BERGENBIO TO PRESENT AT CARNEGIE VIRTUAL NORDIC HEALTHCARE SEMINAR
Bergen, Norway, 17 March 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, is pleased to announce that CEO Martin Olin will be presenting at the Carnegie Virtual Nordic Healthcare Seminar taking place today at 15:15 CET. The presentation will be made available on the Company’s website in the Investors section shortly after the presentation. -Ends- Contacts Martin OlinChief Executive Officer, BerGenBio ASAir@bergenbio.com Rune SkeieChief Financial Officer,